Brad Moore

President and Chief Executive Officer, Roche Diagnostics Corporation
Head of North America Region, Roche Diagnostics

As President and CEO of Roche Diagnostics Corporation, Brad Moore is head of North American commercial operations for the Diagnostics Division of Roche Group, headquartered in Basel, Switzerland. He also serves as a member of Roche's global Diagnostics Leadership Team.

Brad joined Roche in October 2016 as the Head of Diabetes Care North America, where he was responsible for all aspects of Roche's diabetes business in the U.S. and Canada. His responsibilities were expanded to Head of Diabetes Care in North America and Europe, where he was accountable for more than 20 countries. Brad moved to the broader diagnostics business in 2020 as Senior Vice President of Core Lab and Point of Care before being named to his current role in December 2022.

Prior to joining Roche, Brad spent 18 years at Johnson & Johnson, where he most recently served as Vice President of Health System Innovation.

Brad serves on the board of AdvaMedDx, a division of AdvaMed that seeks to advance policy to promote innovation and expand access to quality, in vitro diagnostic testing. He also is on the board of the Central Indiana Corporate Partnership (CICP) to support their mission of advancing the region's continued prosperity and growth. He holds a bachelor's degree in international business from Ohio Wesleyan University.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.